Assay identifies rare tick-borne bacteria: Bobbi Pritt, M.D. - Insights
Bobbi Pritt, M.D., explains how Mayo Clinic Laboratories' new assay identifies less-common tick-borne bacteria in whole blood. The assay is recommended when tick-borne bacterial infection is suspected but standard testing is unrevealing.
Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C., explain how Mayo Clinic Laboratories' targeted test panel facilitates accurate diagnosis of hereditary pancreatitis, which heightens the risk for pancreatic cancer. Test...
Alicia Algeciras-Schimnich, Ph.D., discusses Mayo Clinic Laboratories’ new noninvasive plasma biomarker assay for Alzheimer’s disease, an accessible, highly accurate testing option for individuals age 50 and above who are experiencing mild...
Meet Me at the Microscope at USCAP 2020 - Insights
Mayo Clinic pathologists, researchers, and a wide spectrum of allied health staff will be in Los Angeles, California, for the 109th United States and Canadian Academy of Pathology Meeting (USCAP). Visit us at booth #716 on March 2 - 4, 2020...
MCL @Work: Jessica Balcom - Insights
In 2010, Jessica Balcom began her career with Mayo Clinic supporting molecular testing in the Department of Laboratory Medicine and Pathology with a joint appointment in the Mayo Clinic Cystic Fibrosis Center. Now she serves as a...
Key performance indicators for laboratory outreach programs - Insights
Key performance indicators (KPIs) should be a part of every laboratory’s quality improvement plan, and that includes outreach-specific KPI metrics. Financial, internal-facing, and client-facing KPIs for outreach programs help to create a...
Communiqué Archives - Insights
Skip to Content MayoACCESS MayoLINK...
Industry Archives - Page 2 of 6 - Insights
Skip to Content MayoACCESS MayoLINK...
Industry Archives - Page 3 of 6 - Insights
Skip to Content MayoACCESS MayoLINK...
Cytology: A compelling molecular testing approach - Insights
Learn more about how Mayo Clinic Laboratories is advancing the use of cytology specimens for solid tumor next-generation sequencing.